CEL-SCI Corp CVM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CVM is a good fit for your portfolio.
News
-
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
-
CEL-SCI Corporation Issues Letter to Shareholders
-
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
-
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
-
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
-
CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug
-
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
-
CEL-SCI Reports Productive Meeting with FDA on Cancer Treatment
Trading Information
- Previous Close Price
- $1.50
- Day Range
- $1.50–1.57
- 52-Week Range
- $1.04–3.23
- Bid/Ask
- $1.51 / $1.57
- Market Cap
- $84.21 Mil
- Volume/Avg
- 227,105 / 319,515
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company's core capabilities that include are drug discovery, research, development and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 44
- Website
- https://www.cel-sci.com
Comparables
Valuation
|
Metric
|
CVM
|
VIR
|
CYDY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 5.93 | 0.71 | — |
Price/Sales | — | 28.39 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
CVM
VIR
CYDY
Financial Strength
|
Metric
|
CVM
|
VIR
|
CYDY
|
|---|---|---|---|
Quick Ratio | 0.67 | 8.68 | 0.01 |
Current Ratio | 1.26 | 9.05 | 0.08 |
Interest Coverage | −42.11 | — | −7.55 |
Quick Ratio
CVM
VIR
CYDY
Profitability
|
Metric
|
CVM
|
VIR
|
CYDY
|
|---|---|---|---|
Return on Assets (Normalized) | −69.25% | −20.03% | −363.12% |
Return on Equity (Normalized) | −138.12% | −25.63% | — |
Return on Invested Capital (Normalized) | −74.38% | −28.31% | — |
Return on Assets
CVM
VIR
CYDY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rvzxyvymb | Zdmrb | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bslkzddv | Prgvz | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zskldxnd | Ypmsyy | $98.1 Bil | |
MRNA
| Moderna Inc | Wbphbprlb | Dhc | $39.1 Bil | |
ARGX
| argenx SE ADR | Ysqbxvwn | Wkzcj | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Mvnqmxhnt | Shql | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Lscyvbksv | Gjmdj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nlnjvygf | Skpgjl | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xrqjnmkjhz | Brzmnqk | $12.5 Bil | |
INCY
| Incyte Corp | Fwmgblrb | Ndfzpz | $11.9 Bil |